Adaptive Biotechnologies (ADPT) revenue breakdown
By segment, MRD is the largest at 77% of fiscal 2025 revenue, growing 35% a year over 3 years.
By product, Sequencing Revenue is the largest at 51% of fiscal 2021 revenue; Development Revenue grew fastest, 48% a year over 4 years.
Revenue by segment
Fiscal years, as Adaptive Biotechnologies reports them in its 10-K filings; fiscal 2025 total $277M.
| Segments | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| MRD | $87M | $103M | $146M | $212M | 77% |
| IM | $98M | $68M | $33M | $65M | 23% |
Revenue by product
Fiscal years, as Adaptive Biotechnologies reports them in its 10-K filings; fiscal 2021 total $154M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|
| Sequencing Revenue | $23M | $33M | $44M | $41M | $79M | 51% |
| Development Revenue | $16M | $23M | $42M | $57M | $75M | 49% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ADPT.
Open ADPT in InvestinglyQuestions
Where does Adaptive Biotechnologies make its money?
In fiscal 2025, by segment: MRD $212M, IM $65M.
From Adaptive Biotechnologies's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.